Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

CYTH Insider Trading (Cyclo Therapeutics)

Insider Ownership Percentage: 12.30%
Insider Buying (Last 12 Months): $297,326.22
Insider Selling (Last 12 Months): $0.00

Cyclo Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Share Price & Price History

Current Price: $1.98
Price Change: Price Decrease of -0.07 (-3.41%)
As of 05/20/2022 05:00 PM ET

This chart shows the closing price history over time for CYTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

Cyclo Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2022Jeffrey TateCOOBuy3,000$2.12$6,360.0032,160View SEC Filing Icon  
4/28/2022Jeffrey TateCOOBuy635$2.50$1,587.5027,795View SEC Filing Icon  
3/29/2022Markus SiegerDirectorBuy10,000$2.73$27,300.00View SEC Filing Icon  
2/7/2022N. Scott FineCEOBuy10,334$3.58$36,995.72View SEC Filing Icon  
1/24/2022Francis Patrick OstronicDirectorBuy2,000$3.75$7,500.00View SEC Filing Icon  
1/19/2022Francis Patrick OstronicDirectorBuy1,132$4.00$4,528.00View SEC Filing Icon  
1/19/2022N. Scott FineCEOBuy5,000$3.89$19,450.00View SEC Filing Icon  
1/14/2022Francis Patrick OstronicDirectorBuy2,137$4.00$8,548.00View SEC Filing Icon  
12/15/2021Francis Patrick OstronicDirectorBuy3,000$3.90$11,700.00View SEC Filing Icon  
12/15/2021N. Scott FineCEOBuy5,000$3.89$19,450.00View SEC Filing Icon  
12/3/2021Francis Patrick OstronicDirectorBuy864$4.75$4,104.00View SEC Filing Icon  
12/2/2021Sharon Hemond HrynkowInsiderBuy1,000$4.98$4,980.00View SEC Filing Icon  
12/1/2021Francis Patrick OstronicDirectorBuy5,000$5.00$25,000.00View SEC Filing Icon  
11/19/2021Francis Patrick OstronicDirectorBuy10,652$5.25$55,923.00View SEC Filing Icon  
11/19/2021N. Scott FineCEOBuy5,000$5.25$26,250.00View SEC Filing Icon  
10/29/2021Francis Patrick OstronicDirectorBuy1,000$5.90$5,900.00View SEC Filing Icon  
9/15/2021N. Scott FineCEOBuy5,000$6.35$31,750.00114,666View SEC Filing Icon  
4/16/2021Francis Patrick OstronicDirectorBuy10,000$6.53$65,300.0071,559View SEC Filing Icon  
4/12/2021Francis Patrick OstronicDirectorBuy5,000$7.00$35,000.00
3/29/2021Jeffrey TateCOOBuy2,000$7.50$15,000.0027,160View SEC Filing Icon  
3/29/2021Joshua M. FineCFOBuy50$7.40$370.0016,900View SEC Filing Icon  
3/29/2021Markus SiegerDirectorBuy10,000$8.10$81,000.0059,559View SEC Filing Icon  
3/29/2021Markus SiegerDirectorBuy10,000$8.10$81,000.0067,614View SEC Filing Icon  
3/29/2021Sharon Hemond HrynkowInsiderBuy1,000$7.46$7,460.0018,350View SEC Filing Icon  
3/29/2021Sharon Hemond HrynkowInsiderBuy1,000$7.46$7,460.0018,350View SEC Filing Icon  
1/25/2021Markus SiegerDirectorBuy7,799$6.30$49,133.70View SEC Filing Icon  
12/17/2020Francis Patrick OstronicDirectorBuy30,000$4.66$139,800.00
See Full Table
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

SEC Filings (Institutional Ownership Changes) for Cyclo Therapeutics (NASDAQ:CYTH)

7.10% of Cyclo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CYTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cyclo Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2022Renaissance Technologies LLC75,787$0.24M0.0%+14.3%1.174%Search for SEC Filing on Google Icon
2/17/2022Virtu Financial LLC22,247$83K0.0%N/A0.345%Search for SEC Filing on Google Icon
2/11/2022Geode Capital Management LLC46,848$0.17M0.0%-9.0%0.726%Search for SEC Filing on Google Icon
2/11/2022Renaissance Technologies LLC66,300$0.25M0.0%+532.5%1.027%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Advisers LP12,200$82K0.0%N/A0.189%Search for SEC Filing on Google Icon
11/16/2021UBS Group AG39,914$0.27M0.0%+259.8%0.620%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC51,454$0.35M0.0%+20.8%0.799%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.13,134$88K0.0%+21.1%0.204%Search for SEC Filing on Google Icon
8/16/2021State Street Corp44,700$0.46M0.0%N/A0.703%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC42,577$0.44M0.0%+133.2%0.670%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.151,540$1.55M0.0%+350.4%2.383%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC18,257$0.15M0.0%N/A0.287%Search for SEC Filing on Google Icon
3/26/2021Susquehanna International Group LLP15,656$68K0.0%N/A0.249%Search for SEC Filing on Google Icon
2/17/2021Jane Street Group LLC27,892$0.12M0.0%N/A1.641%Search for SEC Filing on Google Icon
2/17/2021Worth Venture Partners LLC88,690$0.39M0.3%N/A5.217%Search for SEC Filing on Google Icon
2/16/2021Armistice Capital LLC100,000$0.44M0.0%N/A5.882%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Read More on Cyclo Therapeutics

Today's Range

Now: $1.98
Low: $1.95
High: $2.10

50 Day Range

MA: $2.68
Low: $1.98
High: $3.21

52 Week Range

Now: $1.98
Low: $1.88
High: $13.00

Volume

26,605 shs

Average Volume

54,353 shs

Market Capitalization

$16.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cyclo Therapeutics?

Cyclo Therapeutics' top insider investors include:
  1. N Scott Fine (CEO)
  2. Francis Patrick Ostronic (Director)
  3. Markus Sieger (Director)
  4. Jeffrey Tate (COO)
  5. Sharon Hemond Hrynkow (Insider)
  6. Joshua M Fine (CFO)
Learn More about top insider investors at Cyclo Therapeutics.

Who are the major institutional investors of Cyclo Therapeutics?

Cyclo Therapeutics' top institutional shareholders include:
  1. Renaissance Technologies LLC — 1.17%
Learn More about top institutional investors of Cyclo Therapeutics stock.

Which major investors are buying Cyclo Therapeutics stock?

During the previous quarter, CYTH stock was purchased by institutional investors including:
  1. Renaissance Technologies LLC
During the last year, these company insiders have bought Cyclo Therapeutics stock:
  1. N Scott Fine (CEO)
  2. Francis Patrick Ostronic (Director)
  3. Markus Sieger (Director)
  4. Jeffrey Tate (COO)
  5. Sharon Hemond Hrynkow (Insider)
  6. Joshua M Fine (CFO)
Learn More investors buying Cyclo Therapeutics stock.
This is the golden age of investing in artificial intelligence!
A.I. is going to be one of the dominant themes over the next decade, as companies automate their businesses and use A.I. to remain competitive.
Invest in this red-hot industry at pre-IPO prices.